Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464340) titled 'Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: Zodiac Produtos Farmaceuticos S.A.

Condition: Bioequivalence Study in Healthy Subjects

Intervention: Drug: Rivastigmine TDS 9,5 mg/24 h

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 12, 2023

Target Sample Size: 68

Countries of Recruitment: Brazil

To know more, visit https://clinicaltrials.gov/study/NCT07464340...